Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK

Affiliations

¹ UK Departments of Dermatology:, St George's Hospital, St George's University Hospitals NHS Foundation Trust, London.
² Basildon University Hospital, Basildon and Thurrock Hospitals NHS Foundation Trust.
³ Churchill Hospital, Oxford University Hospitals NHS Foundation Trust.
⁴ St Mary's Hospital, Imperial College Healthcare NHS Trust, London.
⁵ Dermatology, Whittington Hospital, Whittington Health NHS Trust, London.
⁶ University Hospital of Wales, Cardiff and Vale University Health Board.
⁷ Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust.
⁸ Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust.
⁹ Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
¹⁰ Royal Free London NHS Foundation Trust.
¹¹ Manchester Royal Infirmary, Manchester University NHS Foundation Trust.
¹² NHS Greater Glasgow and Clyde.
¹³ Queen Margaret Hospital, NHS Fife.
¹⁴ University College Hospital, University College London Hospitals NHS Foundation Trust.
¹⁵ Ninewells Hospital and Medical School, University of Dundee.
¹⁶ Cambridge University Hospitals NHS Foundation Trust.
¹⁷ St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

C E Gollins et al. Br J Dermatol. 2020 Aug.

. 2020 Aug;183(2):394-396.

doi: 10.1111/bjd.18982. Epub 2020 Apr 7.

¹ UK Departments of Dermatology:, St George's Hospital, St George's University Hospitals NHS Foundation Trust, London.
² Basildon University Hospital, Basildon and Thurrock Hospitals NHS Foundation Trust.
³ Churchill Hospital, Oxford University Hospitals NHS Foundation Trust.
⁴ St Mary's Hospital, Imperial College Healthcare NHS Trust, London.
⁵ Dermatology, Whittington Hospital, Whittington Health NHS Trust, London.
⁶ University Hospital of Wales, Cardiff and Vale University Health Board.
⁷ Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust.
⁸ Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust.
⁹ Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
¹⁰ Royal Free London NHS Foundation Trust.
¹¹ Manchester Royal Infirmary, Manchester University NHS Foundation Trust.
¹² NHS Greater Glasgow and Clyde.
¹³ Queen Margaret Hospital, NHS Fife.
¹⁴ University College Hospital, University College London Hospitals NHS Foundation Trust.
¹⁵ Ninewells Hospital and Medical School, University of Dundee.
¹⁶ Cambridge University Hospitals NHS Foundation Trust.
¹⁷ St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

No abstract available

References

1. Venables ZC, Nijsten T, Wong KF et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study. Br J Dermatol 2019; 181:474-82.
1. Chen AC, Martin AJ, Choy B et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373:1618-26.
1. Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin. Carcinogenesis 2013; 34:1144-9.
1. Harwood CA, Mesher D, McGregor JM et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant 2013; 13:119-29.
1. ACTRN12617000599370. Effect of oral nicotinamide (vitamin B3) on skin cancer incidence and actinic keratoses in kidney, liver, heart and lung transplant recipients: a randomised controlled Phase 3 trial. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372709 (last accessed 31 March 2020).